Jan Amstrup

Title: Jan Amstrup: Innovator in Insulin Bioassays

Introduction

Jan Amstrup is a notable inventor based in Greve, Denmark. He has made significant contributions to the field of insulin formulations through his innovative work. His expertise lies in developing methods that enhance the accuracy of insulin potency determination.

Latest Patents

Jan Amstrup holds a patent for a bioassay related to insulin formulations. The invention focuses on a bioassay of insulin peptide in oral formulations and low affinity insulin peptides in liquid formulations. This method quantifies phosphorylated Akt, effectively avoiding the interference of excipients in potency determination. His patent represents a crucial advancement in the field of diabetes treatment.

Career Highlights

Jan Amstrup is associated with Novo Nordisk A/S, a leading global healthcare company specializing in diabetes care. His work at Novo Nordisk has allowed him to contribute to groundbreaking research and development in insulin therapies. His dedication to improving patient outcomes is evident in his innovative approaches.

Collaborations

Throughout his career, Jan has collaborated with esteemed colleagues, including Louise Hjerrild Zeuthen and Thomas Aaskov Pedersen. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Jan Amstrup's contributions to the field of insulin bioassays highlight his commitment to advancing diabetes care. His innovative patent and collaborative efforts with colleagues underscore the importance of teamwork in driving scientific progress.